Vyleesiâ„¢ approved to treat HSDD in premenopausal women

Vyleesi (bremelanotide) is considered a sexual dysfunction drug and is the first specialty drug in this category. It is the second drug approved by the U.S. Food and Drug Administration (FDA) to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.

Vyleesi is an injectable drug with a dose limit of one dose within 24 hours and no more than eight doses per month. The average cost of Vyleesi for a cash-paying customer is $237 per dose.1 The average cost per year would vary depending on use, but could exceed $22,000.1

When coverage of sexual dysfunction drugs either are available through plan design or elected coverage (lifestyle benefit), Vyleesi will require prior authorization to confirm that the use is consistent with the FDA-approved indication and available clinical evidence.

Vyleesi will also be subject to quantity limitations (eight doses per month) consistent with the FDA-recommended dosing. When covered, the formulary tier for Vyleesi depends on the client’s plan design. If the Cigna formulary used by the client does not have a specialty tier, Vyleesi is placed on the Non-Preferred Brand Drug tier. If, however, the Cigna formulary used by the client offers a specialty drug tier, then Vyleesi is placed on the Specialty Drug tier.

  1. Vyleesi Prices, Coupons and Patient Assistance Programs. (Accessed October 22, 2019). Retrieved from https://www.drugs.com/price-guide/vyleesi.

Legal Disclaimer | Privacy | Product Disclosures | Cigna Company Names

Product availability may vary by location and plan type and is subject to change. All group health insurance policies and health benefit plans contain exclusions and limitations. For costs and details of coverage, review your plan documents or contact a Cigna representative.

All Cigna products and service are provided exclusively by or through operating subsidiaries of Cigna Corporation, including Cigna Health and Life Insurance Company, (CHLIC), Evernorth Care Solutions, Inc., Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., Evernorth, Accredo Health Group, Inc., Express Scripts, Inc., ESI Mail Pharmacy Service, Inc., Express Scripts Pharmacy, Inc., Tel-Drug, Inc., Tel-Drug of Pennsylvania, L.L.C., Lynnfield Drug, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. Policy forms: OK - HP-APP-1 et al., OR - HP-POL38 02-13, TN - HP-POL43/HC-CER1V1 et al. (CHLIC). The Cigna name, logo, and other Cigna marks are trademarks of Cigna Intellectual Property, Inc. "Express Scripts" is a trademark of Express Scripts Strategic Development, Inc. This newsletter is not intended for residents of New Mexico.

© 2024 Cigna. All rights reserved